<DOC>
	<DOCNO>NCT00602329</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , leucovorin , oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving bevacizumab together combination chemotherapy may kill tumor cell . Diagnostic procedure , MRI , may help doctor predict patient 's response treatment help plan best treatment . PURPOSE : This randomized phase II trial study well MRI work predict response combination chemotherapy give together bevacizumab treat patient advanced metastatic colorectal cancer .</brief_summary>
	<brief_title>MRI Predicting Response Patients Receiving Combination Chemotherapy Bevacizumab For Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine alteration tumor blood flow use dynamic contrast-enhanced magnetic resonance imaging ( DCE-MRI ) patient advance metastatic colorectal cancer 2 course combination chemotherapy comprise oxaliplatin , fluorouracil , leucovorin ( FOLFOX ) bevacizumab 5 mg/kg v 10 mg/kg FOLFOX alone . Secondary - To correlate tumor blood flow , assess DCE-MRI , time progression patient receive bevacizumab 5mg/kg v 10mg/kg . - To correlate vascular proliferation , measure DCE-MRI , marker endothelial cell proliferation ( i.e. , CD31 , 34 , 105 ; integrin αvß3 ; phospho-ERK ; Ki67 ; PCNA ; smooth muscle actin ) . - To obtain pilot data whether assay measure vascular endothelial cell mitogenic stimulation mitogenic activity may predict response therapy , time progression , overall survival patient receive bevacizumab 5mg/kg v 10mg/kg . - To investigate association various marker apoptosis tumor cell ( e.g. , MIF , CREB , HIF-1-alpha expression/polymorphism others ) tumor vascularity , assess DCE-MRI . - To correlate marker apoptosis tumor cell response therapy , time progression , overall survival . - To determine serum level VEGF prior initiation chemotherapy prior course 2 3 chemotherapy potential marker antiangiogenic activity . OUTLINE : Patients eligible receive bevacizumab randomize 1 2 treatment arm . Patients ineligible receive bevacizumab receive FOLFOX alone . - Arm I : Patients receive leucovorin calcium IV 2 hour oxaliplatin IV 2 hour day 1 fluorouracil IV continuously 46 hour ( FOLFOX ) begin day 1 . Patients also receive bevacizumab 5 mg/kg IV 90 minute day 1 . Treatment repeat every 14 day 6 month absence disease progression unacceptable toxicity . - Arm II : Patients receive FOLFOX arm I bevacizumab 10 mg/kg IV 90 minute day 1 . Treatment repeat every 14 day 6 month absence disease progression unacceptable toxicity . - FOLFOX alone ( control ) : Patients receive FOLFOX arm I . All patient undergo dynamic contrast-enhanced MRI baseline course 2 3 ( day 17 29 ) ass tumor blood flow . Tumor tissue specimen obtain prior colonoscopic biopsy surgical resection patient receive bevacizumab . Tissue specimen examine immunohistochemistry evaluate tumor marker angiogenesis apoptosis ( e.g. , CD31 , 34 , 105 , phospho-ERK , PCNA , Ki67 , SMA , integrin αvß3 ) . Blood specimen obtain baseline prior course 2 3 ( day 15 29 ) evaluate plasma level VEGF . After completion study therapy , patient follow every 2 month 1 year every 3 month thereafter .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced metastatic adenocarcinoma colon rectum Patients receive bevacizumab must tumor tissue available immunohistochemical analysis Formalinfixed , paraffinembedded tissue previous biopsy surgical resection sufficient Measurable disease , define RECIST ≥ 1 lesion accurately measure ≥ 1 dimension ( long diameter record ) ≥ 20 mm conventional technique ( i.e. , CT MRI ) CEA elevation alone insufficient study entry No known brain metastasis PATIENT CHARACTERISTICS : Criteria patient ECOG performance status 01 Life expectancy &gt; 3 month Granulocytes ≥ 1,500/mL Platelet Count ≥ 100,000/mL Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN AST ≤ 5 time ULN Urine protein : creatinine ratio ≤ 1.0 screening Patients prior malignancy eligible , provide treat curative intent evidence recurrence Not pregnant nursing Negative pregnancy test No contraindication MRI , include follow : Hypersensitivity gadolinium Metallic device , include pacemaker , nonMRI compatible aneurysm clip , nonMRIcompatible mechanical and/or electrical device , metallic fragment Severe claustrophobia Additional criterion patient receive bevacizumab : No significant traumatic injury within past 28 day No serious nonhealing wound , ulcer , bone fracture No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No myocardial infarction , unstable angina , cerebrovascular accident within past 6 month No clinically significant peripheral vascular disease No New York Heart Association class IIIV congestive heart failure Patients preexist hypertension stable antihypertensive regimen blood pressure ≤ 150/100 mm Hg study entry PRIOR CONCURRENT THERAPY : Criteria patient Prior adjuvant treatment include oxaliplatin allow No prior bevacizumab At least 14 day since prior radiotherapy recover More 6 month since prior chemotherapy No concurrent investigational agent Additional criterion patient receive bevacizumab : At least 28 day since prior major surgical procedure open biopsy At least 7 day since prior minor surgical procedure ( e.g. , fineneedle aspiration core biopsy ) No anticipation need major surgical procedure study treatment Concurrent oral parenteral anticoagulation therapy allow provide dose stable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>